Ficlatuzumab 产品活性：Ficlatuzumab 是一种靶向人肝细胞生长因子 (HGF) 的单克隆抗体 (McAb)。Ficlatuzumab 能够阻断 HGF/c-Met 信号通路的激活，抑制 c-Met 受体介导的癌细胞增殖、迁移和侵袭。 产品来源： https://www.medchemexpress.cn/ficlatuzumab.html 研究领域：Protein Tyrosine Kinase/RTK 作用靶点：c-Met/HGFR In Vitro: Ficlatuzumab (20 μg/mL; 24 h) effectively decreases tumor-associated fibroblast (TAF)-conditioned media-facilitated HNSCC migration and invasion. Ficlatuzumab (20 μg/mL; 24 h) effectively mitigates TAF-facilitated epithelial-tomesenchymal transition (EMT), Vimentin expression in HNSCC cells. Ficlatuzumab (20 μg/mL; 72 h) reduces proliferation induced by TAF-secreted hepatocyte growth factor (HGF) in HNSCC cells. Ficlatuzumab (20 μg/mL; 16 h) reduces the phosphorylation of c-Met and p44/42 MAPK in HNSCC cells compared with cells treated with recombinant HGF alone. 相关产品：Afatinib | Crizotinib | Cabozantinib | Capmatinib | Savolitinib | Foretinib | Tivantinib | BMS 777607 | PHA-665752 | Merestinib | SU11274 | Telisotuzumab vedotin | Ensartinib dihydrochloride | JNJ-38877605 | Amuvatinib | Tepotinib | Terevalefim | Glesatinib hydrochloride | Zanzalintinib | Golvatinib | Altiratinib | SRI 31215 TFA | Glumetinib | Elzovantinib | Zongertinib | AMG-337 | MK-2461 | Onartuzumab 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。